• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIAID awards SRI International $49M to study new therapies for HIV and AIDS

NIAID awards SRI International $49M to study new therapies for HIV and AIDS

July 28, 2014
CenterWatch Staff

SRI International has been awarded a new $49 million, seven-year contract with the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, to conduct preclinical development of potential therapies for HIV infection and AIDS. The contract supports the development of drugs to treat HIV and AIDS and the complications and opportunistic infections associated with the disease, as well as microbicides for preventing sexual transmission of HIV.

According to the World Health Organization, more than 35 million people are infected with HIV worldwide. Despite major advances in therapeutics to treat HIV and AIDS, more effective and less toxic drugs and preventive interventions, such as microbicides, to prevent the sexual and perinatal transmission of HIV are still needed.

SRI Biosciences scientists will provide integrated preclinical services to assess the pharmacology and toxicology of potential therapeutic agents and microbicides, and to develop, manufacture and analyze preclinical and clinical dosage formulations. These services will help investigators, small companies and NIH staff obtain the data and products needed to acquire additional funding, gain prospective partnerships and fulfill all regulatory requirements for Investigational New Drug (IND) applications. 

The contract renews three existing contracts held by SRI, now rolled into a single contract. One of the contracts, initiated 23 years ago, has supported safety testing of more than 200 drugs and therapeutic vaccines at various stages of development. An additional contract first won by SRI in 2000 supports formulation development and clinical manufacturing of drugs for treatment of HIV. A third pharmaceutical resource contract to conduct analytical chemistry evaluation studies was awarded to SRI in 2007.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing